Blood–brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV

ABSTRACT

Objective: Although blood–brain barrier (BBB) impairment has been reported in HIV-infected individuals, characterization of this impairment has not been clearly defined.

Methods: BBB integrity was measured by CSF/plasma albumin ratio in this cross-sectional study of 631 HIV-infected individuals and 71 controls. We also analyzed CSF and blood HIV RNA and neopterin, CSF leukocyte count, and neurofilament light chain protein (NFL) concentrations. The HIV-infected participants included untreated neuroasymptomatic patients, patients with untreated HIV-associated dementia (HAD), and participants on suppressive antiretroviral treatment (ART).

Results: The albumin ratio was significantly increased in patients with HAD compared to all other groups. There were no significant differences between untreated neuroasymptomatic participants, treated participants, and controls. BBB integrity, however, correlated significantly with CSF leukocyte count, CSF HIV RNA, serum and CSF neopterin, and age in untreated neuroasymptomatic participants. In a multiple linear regression analysis, age, CSF neopterin, and CSF leukocyte count stood out as independent predictors of albumin ratio. A significant correlation was found between albumin ratio and CSF NFL in untreated neuroasymptomatic patients and in participants on ART. Albumin ratio, age, and CD4 cell count were confirmed as independent predictors of CSF NFL in multivariable analysis.

Conclusions: BBB disruption was mainly found in patients with HAD, where BBB damage correlated with CNS immunoactivation. Albumin ratios also correlated with CSF inflammatory markers and NFL in untreated neuroasymptomatic participants. These findings give support to the association among BBB deterioration, intrathecal immunoactivation, and neuronal injury in untreated neuroasymptomatic HIV-infected individuals. Neurology Neuroimmunol Neuroinflamm 2016;3:e300; doi: 10.1212/NXI.0000000000000300

GLOSSARY

ART = antiretroviral therapy; BBB = blood–brain barrier; HAD = HIV-associated dementia; NFL = neurofilament light chain protein.

Impairment of the blood–brain barrier (BBB) is common in patients with HIV encephalitis and important in the pathogenesis of HIV-associated dementia (HAD), but its characterization is incomplete.

CSF viral load and intrathecal immunoactivation, as determined by increased CSF neopterin, correlate with BBB impairment. CNS inflammation also correlates with axonal injury, as measured by CSF concentrations of the light subunit of neurofilament protein (NFL). These findings indicate an association among neuroinflammation, BBB permeability, and neuronal injury, but their relationship has not been fully elucidated.
Initiation of antiretroviral therapy (ART) reduces CSF HIV RNA and various markers of inflammation and neuronal injury. In a study with 38 neuroasymptomatic individuals, only 5% (2/38) had elevated albumin ratios prior to ART initiation: both normalized on treatment. In a recent cross-sectional study, 38.6% of untreated and 24.6% of treated participants had signs of BBB impairment.

The purpose of this study was to define the prevalence of BBB disruption in a large number of treated and untreated HIV-infected individuals at different stages of infection and CNS injury. To test the hypothesis that BBB function is associated with neuroinflammation and CNS injury in HIV, we analyzed associations between albumin ratios and markers of CNS immunoactivation and neuronal injury in samples from predefined patient groups representing essential stages of HIV disease progression and viral suppression.

**METHODS** Patients. In this retrospective cross-sectional study, we analyzed archived CSF samples from 631 HIV-infected adults and 71 HIV-negative controls from 3 centers (Gothenburg, Sweden; San Francisco, CA; and Sydney, Australia). Neurocognitive testing was not routinely performed on participants without any neurologic symptoms or complaints. All participants were clinically assessed for neurologic and neurocognitive symptoms. Those without neurologic complaints or signs at inclusion are referred to as neuroasymptomatic participants. HIV-infected participants were divided into 7 HIV-infected groups: untreated neuroasymptomatic participants, stratified into 4 groups according to CD4 level; untreated participants with HAD, stratified into 2 groups according to severity of dementia; and participants on ART (table 1). The neuroasymptomatic untreated groups were as follows:

1. Neuroasymptomatic with CD4+ T-cell count $>$350 (n = 125); 2. Neuroasymptomatic with CD4+ T-cell count 200–349 (n = 117); 3. Neuroasymptomatic with CD4+ T-cell count 50–199 (n = 102); and 4. Neuroasymptomatic with CD4+ T-cell count $<$50 (n = 71) cells/μL. The 2 groups of patients with HAD were (5) untreated patients with HAD stage 1 (n = 24) and (6) untreated patients with HAD stage 2–4 (n = 33). The final group (7) consisted of participants on ART with plasma HIV RNA $<$50 copies/mL for $\geq$6 months (n = 159). Individuals with CNS opportunistic or other infections, CNS neoplasms, acute cranial nerve palsies, or neurologic diseases with CNS involvement, were excluded. The diagnosis of HAD was based on Centers for Disease Control and Prevention and American Academy of Neurology Task Force Criteria using standard laboratory, neuropsychological testing, and clinical evaluations. Most of the participants were studied before publication of the formal Frascati criteria and were diagnosed with AIDS dementia complex stages 1–4; they met the functional criteria for the Frascati diagnosis of HAD without the requisite extensive formal neuropsychological assessment.

**Standard protocol approvals, registrations, and patient consents.** CSF samples were obtained under the auspices of research protocols approved by the institutional review boards of each of the study sites and in accordance with the Helsinki Declaration, either within the context of studies of the natural history of HIV infection (neuroasymptomatic participants and participants on ART) or during diagnostic evaluations (patients with HAD). All participants gave informed consent, and if their capacity to provide consent was questioned, consent was also obtained from those with power of attorney.

**Methods.** Quantitative determination of CSF and plasma albumin was performed by nephelometry (Behring Nephelometer Analyser, Behringwerke AG, Marburg, Germany). The albumin ratio was calculated as CSF albumin (mg/L)/plasma albumin (g/L) and used to evaluate BBB function. Reference values were <6.8 for individuals younger than 45 years and <10.2 for individuals $\geq$45 years of age. Some CSF samples had been frozen, but never refrozen: regular controls with analyses of biological markers have confirmed compatibility between fresh and frozen samples.

CSF neopterin was analyzed using a commercially available immunoassay (BRAHMS, Berlin, Germany) according to the manufacturer’s instructions. Normal CSF neopterin reference

### Table 1: Patient characteristics

| Groups | No. | Age, y, median (IQR) | Plasma HIV RNA, median log₁₀ (IQR) | CSF HIV RNA, median log₁₀ (IQR) | Blood CD4+ T cells, cells/μL, median (IQR) |
|--------|-----|---------------------|------------------------------------|---------------------------------|---------------------------------------------|
| Cross-sectional study |     |                     |                                    |                                 |                                             |
| Controls | 71  | 43 (35–49)          | —                                  | —                               | 833 (674–1,033)                            |
| NA, CD4 $>$350 | 125 | 38 (30–46)          | 4.12 (3.40–4.55)                   | 3.17 (2.33–3.91)                | 502 (421–650)                              |
| NA, CD4 200–349 | 117 | 39 (31–47)          | 4.77 (4.24–5.17)                   | 3.97 (3.42–4.45)                | 256 (234–300)                              |
| NA, CD4 50–199 | 102 | 37 (32–47)          | 4.92 (4.46–5.42)                   | 3.90 (3.31–4.51)                | 120 (84–163)                               |
| NA, CD4 $<$50 | 71  | 38 (33–47)          | 5.20 (4.53–5.54)                   | 3.07 (2.25–3.76)                | 20 (10–37)                                 |
| HAD stage 1 | 24  | 39 (32–44)          | 5.24 (4.48–5.57)                   | 3.78 (3.27–4.82)                | 55 (21–152)                                |
| HAD stage 2–4 | 33  | 40 (34–46)          | 4.94 (4.07–5.44)                   | 4.94 (4.17–5.44)                | 130 (18–195)                               |
| ART     | 159 | 45 (37–52)          | <1.70                              | <1.70                           | 490 (325–671)                              |

Abbreviations: ART – on antiretroviral treatment with P-RNA $<$50 copies/mL; HAD – HIV-associated dementia (untreated); IQR – interquartile range; NA – neuroasymptomatic (untreated).
Table 2: Albumin ratio, inflammatory markers, and CSF NFL in the different groups of HIV-infected participants and the healthy controls

| Groups        | No. | Albumin ratio, median (IQR) | S-neopterin, nmol/L, median (IQR) | CSF-neopterin, nmol/L, median (IQR) | CSF WBC, cells/μL, median (IQR) | CSF NFL, ng/L, median (IQR) |
|---------------|-----|-----------------------------|-----------------------------------|-------------------------------------|-------------------------------|----------------------------|
| Controls      | 71  | 4.77 (3.91-6.37)            | 6.1 (4.3-8.2)                     | 5.00 (4.1-6.4)                      | 1 (0-2)                       | 407 (331-537)               |
| NA, CD4 >350  | 125 | 4.70 (3.53-6.40)            | 11.1 (8.4-17.9)                  | 11.2 (8.1-17.7)                    | 5 (3-9)                       | 440 (272-580)               |
| NA, CD4 200-349| 117 | 5.15 (4.09-7.00)            | 18.2 (11.2-23.2)                | 18.3 (12.0-26.4)                   | 6 (3-13)                      | 395 (228-640)               |
| NA, CD4 50-199| 102 | 4.90 (3.79-6.86)            | 21.0 (13.6-32.7)                | 21.7 (12.4-32.4)                   | 4 (1-9)                       | 490 (295-886)               |
| NA, CD4 <50   | 71  | 5.00 (3.76-6.21)            | 23.5 (16.5-37.8)                | 22.0 (11.5-35.0)                   | 1 (0-2)                       | 801 (477-2,380)             |
| HAD stage 1   | 24  | 7.37 (5.26-11.31)           | 22.5 (17.0-33.8)                | 29.4 (24.6-61.5)                   | 3 (2-9)                       | 11,400 (5,224-38,225)       |
| HAD stage 2-4 | 33  | 10.42 (7.20-17.00)          | 26.4 (18.2-38.9)                | 75.0 (34.7-127.5)                  | 11 (4-26)                     | 30,825 (25,898-35,753)      |
| ART           | 159 | 4.70 (3.61-6.52)            | 8.4 (5.7-11.0)                  | 6.7 (4.8-9.3)                      | 0 (0-2)                       | 454 (289-673)               |

Abbreviations: ART – on antiretroviral treatment with P-RNA <50 copies/mL; HAD – HIV-associated dementia (untreated); IQR – interquartile range; NA – neuroasymptomatic (untreated); NFL – neurofilament light chain protein; WBC – white blood cells.
CSF biomarker profiles in participants with increased as opposed to normal albumin ratios with respect to age-dependent reference values.

Neuroasymptomatic participants with increased albumin ratios had higher CSF neopterin ($p < 0.05$) and CSF NFL levels ($p < 0.01$). No difference was found in CSF HIV RNA between those groups (figure 2). Patients on suppressive ART and HIV-negative controls with increased albumin ratios had similar levels of CSF neopterin and CSF NFL as participants with normal ratio (not shown).

**Correlations of CSF biomarkers and albumin ratio.** In untreated neuroasymptomatic participants, albumin ratios correlated with CSF leukocyte count ($r = 0.25, p < 0.001$), CSF HIV RNA levels ($r = 0.15, p < 0.01$), blood neopterin ($r = 0.21, p < 0.001$), CSF neopterin ($r = 0.26, p < 0.001$), and age ($r = 0.24, p < 0.001$). Similar correlations with age ($r = 0.27, p = 0.001$) and CSF leukocytes ($r = 0.16, p = 0.05$) were found in virally suppressed participants. In HIV-negative controls, only age correlated significantly with albumin ratio ($r = 0.26, p < 0.05$). No significant correlations were found between CSF neopterin and albumin ratio in participants on suppressive ART or in HIV-negative controls. There was no significant correlation between CD4 nadir and albumin ratio in virally suppressed participants. While all participants on ART had plasma HIV RNA levels <50 copies/mL as part of the inclusion criteria, 5 out of 159 treated participants (3.1%) had detectable HIV RNA levels in the CSF, ranging from 50 to 145 copies/mL.

In a multiple linear regression analysis, age, CSF neopterin, and CSF leukocyte count stood out as independent predictors of albumin ratios in neuroasymptomatic participants (table 3).

**Correlations between albumin ratio and CSF NFL.** A significant correlation was found between the albumin ratio and CSF NFL concentration in untreated neuroasymptomatic participants ($r = 0.32, p < 0.001$).

Albumin ratio was confirmed as an independent predictor of CSF NFL together with age and CD4 cell count in a multiple linear regression analysis. By contrast, CSF HIV RNA and CSF neopterin were not found to be significant predictors (table 4).

Albumin ratios and CSF NFL levels were also correlated in participants on ART ($r = 0.44, p < 0.001$) and albumin ratios were, together with age, confirmed as independent predictors of CSF NFL in multivariable analysis (data not shown). Likewise, a significant correlation was found between albumin ratios and CSF NFL concentrations in HIV-negative controls ($r = 0.30, p < 0.05$). CSF NFL results were missing in the majority of patients with HAD because of shortage of samples.

**DISCUSSION** BBB impairment is considered a key event in CNS injury in HIV infection. To date, this is the largest study that has characterized the BBB in
treated and untreated HIV-infected individuals at different stages of infection, and with varying degrees of neurocognitive impairment. A majority of the participants with HAD (68%) had elevated albumin ratios, compared with 16% of untreated neuroasymptomatic individuals. This is broadly consistent with previous smaller studies, where the prevalence of BBB dysfunction has been shown to increase as the HIV infection progresses.3,15 In contrast to earlier publications that have been fairly small or based on case reports, this study extends the characterization of BBB dysfunction and its relationship to neuroinflammation and CNS injury to this rather large cohort of thoroughly classified participants with HIV infection. This is a major strength of the study and makes the results more reliable.

Although most neuroasymptomatic HIV-infected participants without ART had albumin ratios within the normal range, we found a significant correlation between CSF neopterin, a marker of intrathecal immune activation, and BBB integrity in this group. CNS inflammation was, together with age, confirmed in a multivariable analysis as independent predictors of BBB impairment. Intrathecal immune activation is a general feature of HIV infection, and a persistent low-grade immune activation is often present even in antiretroviral treated patients despite several years of suppressed plasma viral loads.7,18 However, CSF neopterin did not correlate with albumin ratios in patients on suppressive ART, or in healthy controls, perhaps because substantial CNS inflammation is required for BBB impairment.

In addition, we found the albumin ratio to be an independent predictor of CSF NFL both in untreated and treated HIV-infected individuals, suggesting that minor impairment of the BBB might be harmful to the CNS. However, the lack of association with markers of immune activation in patients on treatment implies either an additional mechanism or possibly fixed BBB impairment as a legacy effect of pre-ART disease. Another recent study on treated HIV-infected individuals undergoing lumbar punctures for clinical reasons reported a similar association between albumin ratios and the neural protein t-tau, but without any association with CSF neopterin.19 NFL is a more sensitive marker of neural injury than t-tau20 and our study corroborates the association between BBB function and CNS disturbance, extending it also to untreated and treated HIV-infected participants without neurologic symptoms.

The BBB is a semipermeable barrier surrounding the CNS. Its main function is to maintain a stable environment for the brain. It differs from other capillaries in the body in a number of ways. Most importantly, endothelial cells in the BBB are fused together by tight junctions.21 HIV-infected cells in the CNS and the periphery produce viral proteins such as gp120, Tat, and Nef, and inflammatory mediators including cytokines and chemokines.22 These viral and host products have the ability to affect the integrity of the BBB, leading to increased permeability of the brain endothelial cells. Impairment of the BBB could be harmful to the brain by facilitating influx of blood proteins, viral particles, and other possibly neurotoxic substances into the CNS (figure e-1 at Neurology.org/nn). Conversely, BBB impairment may facilitate entry of antiretroviral drugs, which may be beneficial. The BBB restricts the entry of proteins from the blood to the brain and the CSF.
resulting in markedly lower concentrations of proteins in CSF than in blood. Because albumin is exclusively synthesized in the liver, albumin detected in CSF originates from blood. The albumin ratio between CSF and plasma provides a reliable determination of BBB function,1,3,24 and is the most commonly used method to examine this.

Myelinated axons consist of a major structural element NFL, the light subunit of the neurofilament protein. Previous studies have confirmed CSF NFL concentrations as a reliable marker of CNS axonal injury in various neurodegenerative diseases25 including CNS injury associated with HIV infection.5,26 Increased CSF NFL is a consistent finding in patients with HAD, but can also be found in some HIV-infected patients without neurologic symptoms, mainly in individuals with low CD4 + T-cell counts. Our study confirms immunosuppression and age as predictors of CSF NFL in multivariable analysis. In addition, we found that impairment of the BBB was an independent predictor of axonal injury. A significant correlation was found between the albumin ratio and CSF NFL in both untreated and treated individuals, supporting the hypothesis that increased BBB permeability may be linked with neuronal injury in HIV infection. Neurotoxic substances and inflammation may cause damage to neuroglial cells further amplifying BBB breakdown, eventually leading to clinically significant neurocognitive deficits.

In agreement with previous smaller studies,3 we found no correlation between CD4+ T-cell count and BBB dysfunction. Another recent study found that increased BBB permeability was more common in individuals on ART with low CD4 nadir compared with those with high CD4 nadir.9 We could not confirm this finding in our study, where no correlation was found between CD4 nadir and the albumin ratio in patients on suppressive ART. In contrast to the abovementioned study, all treated participants in our study were virologically suppressed, which might explain the diverse results. Furthermore, in the current study, participants were asymptomatic, with lumbar punctures performed within clinical study protocols and not for clinical reasons.

Also in agreement with previous studies,9 we did not find any difference in the albumin ratio between neuroasymptomatic HIV-infected participants and patients on ART. However, those were cross-sectional studies and the data are sparse on BBB integrity changes following initiation of ART.8 Neither has the effect of ART on BBB integrity in patients with HAD and increased albumin ratios been carefully elucidated. Smaller studies and case reports indicate that normalization of the albumin ratio, even in patients with HAD, is possible after commencement of ART.8,27

Almost one-fifth of untreated neuroasymptomatic participants, some of them with preserved immune systems, had signs of BBB impairment. Patients in the neuroasymptomatic groups had neither neuropsychological symptoms, signs, or complaints, but as neuropsychological testing was not performed on all participants, we cannot exclude the possibility that some had asymptomatic neurocognitive impairment. It is not known if asymptomatic patients with elevated albumin ratios have an increased risk of developing symptomatic neurocognitive deficits in the future. It is notable that the proportion of asymptomatic untreated patients with impaired BBB had significantly higher levels of both CSF neopterin and CSF NFL compared with patients without BBB injury, while no such difference was found in participants on suppressive ART or in healthy controls.

We have previously found that CSF NFL can predict severe neurocognitive impairment.28 Impairment of BBB with simultaneously raised levels of CSF neopterin and CSF NFL give further support to the association among BBB deterioration, neuroinflammation, and axonal injury in untreated HIV. Indeed, our results point to the potential utility of measurement of the albumin ratio, something which is simple and easily performed. Further, our data allow the generation of 2 important hypotheses. First, albumin ratio elevation in neuroasymptomatic patients may predict the subsequent development of HIV-associated neurocognitive disorders. Second, there is no need for antiretroviral drugs that penetrate the brain if the albumin ratio is normal. Further prospective studies can address these hypotheses.

AUTHOR CONTRIBUTIONS
M.G. originated the idea and designed and supervised the study. M.G., A.Y., L.H.B., and R.W.P. recruited the participants. D.F. and H.Z. performed the biochemical analyses. B.A. and M.G. performed acquisition, analysis, and interpretation of data. B.A., M.G., and S.N. performed the statistics. B.A., A.Y., and M.G. wrote the article. All the authors contributed to manuscript preparation.

STUDY FUNDING
Supported by the Swedish Research Council (K2011-58P-20931-01-4, 2013-2546), the Sahlgrenska University Hospital (ALFGBG-430271, ALFGBG-441051), the Knut and Alice Wallenberg Foundation, and the NIH (RO1MH62701, R21MH096619, R21NS069219 and UL1 TR000004).

DISCLOSURE
B. Anesten and A. Yilmaz report no disclosures. L. Hagberg serves as an associate editor for Infectious Diseases. H. Zetterberg served as an associate editor for Journal of Alzheimer’s Disease, Alzheimer’s & Dementia, and DADM; is cofounder of Brain Biomarker Solutions in Gothenburg AB; and received research support from The Swedish Research Council, Swedish State Support for Clinical Research, VINNOVA, The Knut and Alice Wallenberg Foundation, The European Research Council, and Frimurarestiftelsen. S. Nilsson reports no disclosures. B. Brew served on the scientific advisory board for Biogen Idec Viiv, received speaker

© 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
REFERENCES

1. Valcour V, Chalermechai T, Sailasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis 2012;206:275–282.

2. Gisslen M, Chiiodi F, Fuchs D, et al. Markers of immune stimulation in the cerebrospinal fluid during HIV infection: a longitudinal study. Scand J Infect Dis 1994;26:523–533.

3. Andersson LM, Hagberg L, Fuchs D, Svennetholm B, Gisslen M. Increased blood-brain barrier permeability in neuro-a symmetric HIV-1-infected individuals: correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels. J Neurovirol 2001;7:542–547.

4. Persidsky Y, Zheng J, Miller D, Gendelman HE. Mononuclear phagocytes mediate blood-brain barrier compromise and neuronal injury during HIV-1-associated dementia. J Leukoc Biol 2006;80:413–422.

5. Jessen Krut J, Mellberg T, Price RW, et al. Biomarker evidence of axonal injury in neuroasymmetric HIV-1 patients. PLoS One 2014;9:e88591.

6. Mellgren A, Antinori A, Cinque P, et al. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther 2005;10:701–707.

7. Yilmaz A, Yiannoutsos CT, Fuchs D, et al. Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. J Neuroinflammation 2013;10:62.

8. Abdulle S, Hagberg L, Gisslen M. Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymmetric HIV-1-infected patients. HIV Med 2005;6:164–169.

9. Calcagno A, Alberione MC, Romito A, et al. Prevalence and predictors of blood-brain barrier damage in the HAART era. J Neurovirol 2014;20:521–525.

10. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988;158:1079–1083.

11. Antinori A, Arendt G, Becker JT, et al. Updated research nomenclature for HIV-associated neurocognitive disorders. Neurology 2007;69:1789–1799.

12. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus type 1 (HIV-1) infection: report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 1991;41:778–785.

13. Blennow K, Fredman P, Wallin A, et al. Protein analysis in cerebrospinal fluid: II: reference values derived from healthy individuals 18–88 years of age. Eur Neurol 1993;33:129–133.

14. Hagberg L, Cinque P, Gisslen M, et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther 2010;7:15.

15. Marshall DW, Brey RL, Cahill WT, Houk RW, Zajac RA, Boswell RN. Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection. Arch Neurol 1988;45:954–958.

16. Petito CK, Cash KS. Blood-brain barrier abnormalities in the acquired immunodeficiency syndrome: immunohistochemical localization of serum proteins in postmortem brain. Ann Neurol 1992;32:658–666.

17. Power C, Kong PA, Crawford TO, et al. Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier. Ann Neurol 1993;34:339–350.

18. Eden A, Price RW, Spadich S, Fuchs D, Hagberg L, Gisslen M. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis 2007;196:1779–1783.

19. Calcagno A, Atzori C, Romito A, et al. Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients. J Neurovirol 2015;21:88–92.

20. Peterson J, Gisslen M, Zetterberg H, et al. Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection. PLoS One 2014;9:e116081.

21. Wong AD, Ye M, Levy AF, Rothstein JD, Bergles DE, Scarsel PC. The blood-brain barrier: an engineering perspective. Front Neuroeng 2013;6:7.

22. Strazza M, Pirrone V, Wijdahl B, Nonnemacher MR. Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res 2011;1399:96–115.

23. Banks WA, Robinson SM, Nath A. Permeability of the blood-brain barrier to HIV-1 Tat. Exp Neurol 2005;193:218–227.

24. Tibbling L, Link H, Ohlman S. Principles of albumin and IgG analyses in neurological disorders: I: establishment of reference values. Scand J Clin Lab Invest 1977; 37:385–390.

25. Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol 2014;75:116–126.

26. Abdulle S, Mellgren A, Brew BJ, et al. CSF neurofilament protein (NFL): a marker of active HIV-related neurodegeneration. J Neurol 2007;254:1026–1032.

27. Andersson LM, Hagberg L, Rosengren L, et al. Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis 2007;195:1774–1778.
Blood–brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV

Birgitta Anesten, Aylin Yılmaz, Lars Hagberg, et al.

Neurol Neuroimmunol Neuroinflamm 2016;3;
DOI 10.1212/NXI.0000000000000300

This information is current as of November 9, 2016
| **Updated Information & Services** | including high resolution figures, can be found at: [http://nn.neurology.org/content/3/6/e300.full.html](http://nn.neurology.org/content/3/6/e300.full.html) |
|-------------------------------|--------------------------------------------------------------------------------------------------|
| **Supplementary Material** | Supplementary material can be found at: [http://nn.neurology.org/content/suppl/2016/11/09/3.6.e300.DC1](http://nn.neurology.org/content/suppl/2016/11/09/3.6.e300.DC1) |
| **References** | This article cites 28 articles, 0 of which you can access for free at: [http://nn.neurology.org/content/3/6/e300.full.html##ref-list-1](http://nn.neurology.org/content/3/6/e300.full.html##ref-list-1) |
| **Citations** | This article has been cited by 2 HighWire-hosted articles: [http://nn.neurology.org/content/3/6/e300.full.html##otherarticles](http://nn.neurology.org/content/3/6/e300.full.html##otherarticles) |
| **Subspecialty Collections** | This article, along with others on similar topics, appears in the following collection(s):  
**All Cognitive Disorders/Dementia** [http://nn.neurology.org/cgi/collection/all_cognitive_disorders_dementia](http://nn.neurology.org/cgi/collection/all_cognitive_disorders_dementia)  
**All Immunology** [http://nn.neurology.org/cgi/collection/all_immunology](http://nn.neurology.org/cgi/collection/all_immunology)  
**HIV** [http://nn.neurology.org/cgi/collection/hiv](http://nn.neurology.org/cgi/collection/hiv)  
**HIV dementia** [http://nn.neurology.org/cgi/collection/hiv_dementia](http://nn.neurology.org/cgi/collection/hiv_dementia)  
**Viral infections** [http://nn.neurology.org/cgi/collection/viral_infections](http://nn.neurology.org/cgi/collection/viral_infections) |
| **Permissions & Licensing** | Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: [http://nn.neurology.org/misc/about.xhtml#permissions](http://nn.neurology.org/misc/about.xhtml#permissions) |
| **Reprints** | Information about ordering reprints can be found online: [http://nn.neurology.org/misc/addir.xhtml#reprintsus](http://nn.neurology.org/misc/addir.xhtml#reprintsus) |